Form 4 for EW Edwards Lifesciences
Accepted 2023-05-09 00:00:00 ET · period of report 2023-05-07 · accession 0001225208-23-005617 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-05-09 | 2023-05-07+ | EW | Lemercier Jean-Luc M | CVP, EMEACLA, JAPAC | F - Tax | $88.74 | -328 | 172.2K | -0.2% | -$29.1K |
| DM | 2023-05-09 | 2023-05-07+ | EW | Lemercier Jean-Luc M | CVP, EMEACLA, JAPAC | M - OptEx | $23.38 | +9,995 | 172.4K | +6% | +$233.7K |
| D | 2023-05-09 | 2023-05-09 | EW | Lemercier Jean-Luc M | CVP, EMEACLA, JAPAC | S - Sale+OE | $88.68 | -6,640 | 172.1K | -4% | -$588.8K |
| DM | 2023-05-09 | 2023-05-07+ | EW | Lemercier Jean-Luc M | CVP, EMEACLA, JAPAC | M - OptEx | $0.00 | -9,995 | 920 | -92% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-08 | F | D | 104 | $88.74 | 172,089.78 | D | — | — | |
| 2 | Common | Common Stock | 2023-05-09 | M | A | 6,640 | $35.20 | 178,729.78 | D | — | — | |
| 3 | Common | Common Stock | 2023-05-07 | M | A | 3,355 | $0.00 | 172,417.78 | D | — | — | (F1) On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4. |
| 4 | Common | Common Stock | 2023-05-09 | S | D | 6,640 | $88.68 | 172,089.78 | D | — | — | |
| 5 | Common | Common Stock | 2023-05-07 | F | D | 224 | $88.74 | 172,193.78 | D | — | — | |
| 6 | Derivative | Employee Stock Option (Right to Acquire) | 2023-05-09 | M | D | 6,640 | $0.00 | 0 | D | $35.20 · 2017-05-12 to 2023-05-11 | 6,640 Common Stock | |
| 7 | Derivative | Performance Rights | 2023-05-07 | M | D | 3,355 | $0.00 | 920 | D | — · 2023-05-07 to 2027-05-06 | 3,355 Common Stock | (F1) On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4. |